This Article Full Text Full Text (PDF) All Versions of this Article: 34/8/1981    most recent 01.STR.0000080381.76409.B2v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prass, K. Articles by Meisel, A. Search for Related Content PubMed PubMed Citation Articles by Prass, K. Articles by Meisel, A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Other Research Animal models of human disease Gene expression Physiological and pathological control of gene expression

(Stroke. 2003;34:1981.)
© 2003 American Heart Association, Inc.

Original Contributions

Hypoxia-Induced Stroke Tolerance in the Mouse Is Mediated by Erythropoietin

Konstantin Prass, MD; Anna Scharff; Karsten Ruscher; Diana Löwl; Claudia Muselmann; Ilya Victorov, MD; Krisztian Kapinya, MD; Ulrich Dirnagl, MD Andreas Meisel, MD

From the Department of Neurology, Medical Faculty Charité, Humboldt University, Berlin, Germany (K.P., A.S., K.R., D.L., C.M., K.K., U.D., A.M.), and Brain Research Institute, Russian Academy of Sciences, Moscow, Russia (I.V.).

Reprint requests to Dr Andreas Meisel, Department of Neurology, Humboldt University Berlin, Schumannstrasse 20-21, 10098 Berlin, Germany. E-mail andreas.meisel{at}charite.de

Background and Purpose— Cellular response to hypoxia is mainly controlled by hypoxia-inducible factor 1 (HIF-1). The HIF-1 target gene erythropoietin (EPO) has been described as neuroprotective. Thus, we hypothesize EPO to be an essential mediator of protection in hypoxic preconditioning.

Methods— We randomized Sv129 mice into groups for different pretreatments, different hypoxia-ischemia intervals, or different durations of ischemia. For hypoxic preconditioning, the animals were exposed to a hypoxic gas mixture (8% O₂ and 92% N₂) for 30, 60, 180, 300, or 360 minutes. At 0, 24, 48, 72, or 144 hours later, we performed middle cerebral artery occlusion and allowed reperfusion after 30, 45, 60, or 120 minutes, or occlusion was left to be permanent. We studied EPO gene expression in brain tissue with a real-time reverse transcriptase-polymerase chain reaction and measured HIF-1 DNA-binding activity with an electrophoretic mobility shift assay. To block endogenously produced EPO, we instilled soluble EPO receptor into the cerebral ventricle.

Results— Hypoxic preconditioning for 180 or 300 minutes induced relative tolerance to transient focal cerebral ischemia, as evidenced by a reduction of infarct volumes to 75% or 54% of the control, respectively. Hypoxic pretreatment was effective only when applied 48 or 72 hours before middle cerebral artery occlusion. Sixty minutes after hypoxia, we found a marked activation of HIF-1 DNA-binding activity and a 7-fold induction of EPO transcription. Infusion of soluble EPO receptor significantly reduced the protective effect of hypoxic pretreatment by 40%.

Conclusions— Endogenously produced EPO is an essential mediator of ischemic preconditioning.

Key Words: erythropoietin • ischemic preconditioning • stroke • transcription factors • mice

This article has been cited by other articles:

				M. E. Jung, J. W. Simpkins, A. M. Wilson, H. F. Downey, and R. T. Mallet Intermittent hypoxia conditioning prevents behavioral deficit and brain oxidative stress in ethanol-withdrawn rats J Appl Physiol, August 1, 2008; 105(2): 510 - 517. [Abstract] [Full Text] [PDF]

				J. Zhang, Z.-J. Yang, J. A. Klaus, R. C. Koehler, and J. Huang Delayed Tolerance With Repetitive Transient Focal Ischemic Preconditioning in the Mouse Stroke, March 1, 2008; 39(3): 967 - 974. [Abstract] [Full Text] [PDF]

				Z.-Y. Chen, P. Asavaritikrai, J. T. Prchal, and C. T. Noguchi Endogenous Erythropoietin Signaling Is Required for Normal Neural Progenitor Cell Proliferation J. Biol. Chem., August 31, 2007; 282(35): 25875 - 25883. [Abstract] [Full Text] [PDF]

				C. Harms, K. Albrecht, U. Harms, K. Seidel, L. Hauck, T. Baldinger, D. Hubner, G. Kronenberg, J. An, K. Ruscher, et al. Phosphatidylinositol 3-Akt-Kinase-Dependent Phosphorylation of p21Waf1/Cip1 as a Novel Mechanism of Neuroprotection by Glucocorticoids J. Neurosci., April 25, 2007; 27(17): 4562 - 4571. [Abstract] [Full Text] [PDF]

				J. A. Westberg, M. Serlachius, P. Lankila, M. Penkowa, J. Hidalgo, and L. C. Andersson Hypoxic Preconditioning Induces Neuroprotective Stanniocalcin-1 in Brain via IL-6 Signaling Stroke, March 1, 2007; 38(3): 1025 - 1030. [Abstract] [Full Text] [PDF]

				M. Fantacci, P. Bianciardi, A. Caretti, T. R. Coleman, A. Cerami, M. Brines, and M. Samaja Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia PNAS, November 14, 2006; 103(46): 17531 - 17536. [Abstract] [Full Text] [PDF]

				J. C. Chavez, O. Baranova, J. Lin, and P. Pichiule The Transcriptional Activator Hypoxia Inducible Factor 2 (HIF-2/EPAS-1) Regulates the Oxygen-Dependent Expression of Erythropoietin in Cortical Astrocytes J. Neurosci., September 13, 2006; 26(37): 9471 - 9481. [Abstract] [Full Text] [PDF]

				K. R. Dave, R. Prado, A. P. Raval, K. L. Drew, and M. A. Perez-Pinzon The Arctic Ground Squirrel Brain Is Resistant to Injury From Cardiac Arrest During Euthermia Stroke, May 1, 2006; 37(5): 1261 - 1265. [Abstract] [Full Text] [PDF]

				F. Kerendi, M. E. Halkos, H. Kin, J. S. Corvera, D. J. Brat, M. B. Wagner, J. Vinten-Johansen, Z.-Q. Zhao, J. M. Forbess, K. R. Kanter, et al. Upregulation of hypoxia inducible factor is associated with attenuation of neuronal injury in neonatal piglets undergoing deep hypothermic circulatory arrest J. Thorac. Cardiovasc. Surg., October 1, 2005; 130(4): 1079 - 1079. [Abstract] [Full Text] [PDF]

				J. Liu, P. Narasimhan, F. Yu, and P. H. Chan Neuroprotection by Hypoxic Preconditioning Involves Oxidative Stress-Mediated Expression of Hypoxia-Inducible Factor and Erythropoietin Stroke, June 1, 2005; 36(6): 1264 - 1269. [Abstract] [Full Text] [PDF]

				T. Rui, Q. Feng, M. Lei, T. Peng, J. Zhang, M. Xu, E. Dale Abel, A. Xenocostas, and P. R. Kvietys Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1 Cardiovasc Res, February 15, 2005; 65(3): 719 - 727. [Abstract] [Full Text] [PDF]

				T. Acker and H. Acker Cellular oxygen sensing need in CNS function: physiological and pathological implications J. Exp. Biol., August 15, 2004; 207(18): 3171 - 3188. [Abstract] [Full Text] [PDF]

				H. H. Marti Erythropoietin and the hypoxic brain J. Exp. Biol., August 15, 2004; 207(18): 3233 - 3242. [Abstract] [Full Text] [PDF]

				A. Gendron, E. Kouassi, S. Nuara, C. Cossette, G. D'Angelo, D. Geadah, P. du Souich, and J. Teitelbaum Transient Middle Cerebral Artery Occlusion Influence on Systemic Oxygen Homeostasis and Erythropoiesis in Wistar Rats Stroke, August 1, 2004; 35(8): 1979 - 1984. [Abstract] [Full Text] [PDF]

				M. A Bogoyevitch An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection Cardiovasc Res, August 1, 2004; 63(2): 208 - 216. [Abstract] [Full Text] [PDF]

				G. Grasso, A. Sfacteria, A. Cerami, and M. Brines Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go? Neuroscientist, April 1, 2004; 10(2): 93 - 98. [Abstract] [PDF]